Skip to content
OpenCapital
Get started

Zoetis ZTS Pain and sedation — Revenue

Other product segments

Horses
$5.8B+13.9%
Dogs and Cats
$1.35B+11.6%
Parasiticides
$586M+2.4%
Vaccines
$519M+18.2%
Cattle
$399M-0.5%
Dermatology
$349M-7.9%
Anti-infectives
$241M+1.3%
Other pharmaceutical
$158M0.0%
Swine
$128M-7.9%
Animal health diagnostics
$117M+12.5%
Poultry
$117M-7.9%
Other Non Pharmaceuticals
$66M-7.0%
Fish
$65M+4.8%
Contract manufacturing & human health
$23M-23.3%
Sheep and other
$17M+6.3%

Similar metrics at other companies

AtriCure logo
ATRCPain management — Revenue from Contract with Customer, Excluding Assessed Tax
$24.35M+27.8%
Cencora logo
CORAnimal Health — Revenue
$1.44B+5.3%
Perrigo Company logo
PRGOPain & Sleep — Net Sales
$106.6M-17.8%
Elanco Animal Health Inc. logo
ELANPet Health — Revenue
$710M+11.8%
Bioventus logo
BVSPain Treatments — Total Net Sales
$63.43M+7.7%
PBH
PBHAnalgesics — Total revenues
$28.24M-6.5%

Other financials

Income statement

See full
Revenue$2.3B+2.9%
Gross profit$1.6B+2.6%
Net income$601.0M-0.2%
EPS (diluted)$1.42+6.0%

Balance sheet

See full
Cash & equivalents$1.9B+8.9%
Total debt$10.0B+48.0%
Total equity$3.2B-30.5%
Total assets$15.2B+7.5%

Cash flow

See full
Operating cash flow$401.0M-22.1%
CapEx$110.0M-38.2%
Free cash flow$291.0M-13.6%

Valuation

See full
Market cap$31.9B-54.6%
Enterprise value$39.95B-47.2%
P/E12.1×-15.1×
P/S3.4×-4.1×

Profitability

See full
Gross margin71.8%+0.8pp
Net margin27.8%+0.9pp
FCF margin23.5%0.0pp

Returns & leverage

See full
Return on equity67%+15.8pp
Debt / equity3.1×+1.6×
Current ratio3.2×+1.4×

Where this comes from

Reported directly by Zoetis in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Zoetis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zoetis's pain and sedation — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zoetis's pain and sedation — revenue?
Zoetis (ZTS) reported pain and sedation — revenue of $203M in Q1 2026.
How has Zoetis's pain and sedation — revenue changed year-over-year?
Zoetis's pain and sedation — revenue decreased by 1.9% year-over-year, from $207M to $203M.
What is the long-term trend for Zoetis's pain and sedation — revenue?
Over 3 years (2022 to 2025), Zoetis's pain and sedation — revenue has grown at a 25.8% compound annual growth rate (CAGR), from $420M to $837M.
What does pain and sedation — revenue mean?
This metric represents the total revenue generated from the sale of pharmaceutical products specifically designed for pain management and sedation in animals. It captures the financial performance of a specialized therapeutic category that serves both companion and production animal markets. This segment is a key indicator of the company's ability to capitalize on the growing demand for advanced veterinary care and chronic condition management.